ABREVA Drug Patent Profile
✉ Email this page to a colleague
Which patents cover Abreva, and what generic alternatives are available?
Abreva is a drug marketed by Haleon Us Holdings and is included in one NDA.
The generic ingredient in ABREVA is docosanol. There are five drug master file entries for this compound. Thirty-nine suppliers are listed for this compound. Additional details are available on the docosanol profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for Abreva
A generic version of ABREVA was approved as docosanol by P AND L on November 19th, 2018.
AI Research Assistant
Questions you can ask:
- What is the 5 year forecast for ABREVA?
- What are the global sales for ABREVA?
- What is Average Wholesale Price for ABREVA?
Summary for ABREVA
| US Patents: | 0 |
| Applicants: | 1 |
| NDAs: | 1 |
| Finished Product Suppliers / Packagers: | 1 |
| Raw Ingredient (Bulk) Api Vendors: | 122 |
| Clinical Trials: | 1 |
| Drug Prices: | Drug price information for ABREVA |
| What excipients (inactive ingredients) are in ABREVA? | ABREVA excipients list |
| DailyMed Link: | ABREVA at DailyMed |
Recent Clinical Trials for ABREVA
Identify potential brand extensions & 505(b)(2) entrants
| Sponsor | Phase |
|---|---|
| University of Utah | Phase 2 |
US Patents and Regulatory Information for ABREVA
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Haleon Us Holdings | ABREVA | docosanol | CREAM;TOPICAL | 020941-001 | Jul 25, 2000 | OTC | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Expired US Patents for ABREVA
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
|---|---|---|---|---|---|---|---|
| Haleon Us Holdings | ABREVA | docosanol | CREAM;TOPICAL | 020941-001 | Jul 25, 2000 | ⤷ Sign Up | ⤷ Sign Up |
| Haleon Us Holdings | ABREVA | docosanol | CREAM;TOPICAL | 020941-001 | Jul 25, 2000 | ⤷ Sign Up | ⤷ Sign Up |
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
International Patents for ABREVA
See the table below for patents covering ABREVA around the world.
| Country | Patent Number | Title | Estimated Expiration |
|---|---|---|---|
| European Patent Office | 0428642 | USE OF C-22 TO C-26 ALIPHATIC ALCOHOLS IN THE TREATMENT OF INFLAMMATORY AND VIRAL SKIN DISEASES | ⤷ Sign Up |
| China | 1419911 | ⤷ Sign Up | |
| European Patent Office | 1473031 | Formulations d'alcool C20 à C28 à base d'ester de sucrose (Sucrose ester - C20 to C28 alcohol formulations) | ⤷ Sign Up |
| >Country | >Patent Number | >Title | >Estimated Expiration |
Supplementary Protection Certificates for ABREVA
| Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
|---|---|---|---|---|
| 0428642 | 07C0081 | France | ⤷ Sign Up | PRODUCT NAME: DOCOSANOL; REGISTRATION NO/DATE IN FRANCE: NL 33457 DU 20070821; REGISTRATION NO/DATE AT EEC: 18517 DU 20031114 |
| 0428642 | 57/2007 | Austria | ⤷ Sign Up | PRODUCT NAME: DOCOSANOL; NAT. REGISTRATION NO/DATE: 1-27014 20070518; FIRST REGISTRATION: SE 18517 20031114 |
| 0428642 | 300354 | Netherlands | ⤷ Sign Up | 300354, 20100416, EXPIRES: 20150415 |
| >Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |
Make Better Decisions: Try a trial or see plans & pricing
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
ISSN: 2162-2639
Privacy and Cookies
Terms & Conditions
Site Map
DrugPatentWatch Alternatives
LOE / Major Patent Expirations 2024 - 2025
NCE-1 Patent Challenge Dates 2024 - 2025
Trigger-based marketing for the life sciences
Get DrugPatentWatch Business Intelligence Reports at Amazon.com
DrugChatter - AI-based answers to questions about drugs
RxJam - Digital Marketing for Life Sciences
Friedman, Yali. "DrugPatentWatch" DrugPatentWatch, thinkBiotech, 2024, www.DrugPatentWatch.com.
See Primary Research Papers Citing DrugPatentWatch
Follow DrugPatentWatch:
